Incanthera Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
INC
- Investments
-
3
- Share Price
-
$0.07
- (As of Wednesday Closing)
Incanthera General Information
Description
Incanthera PLC is a UK-based dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. It has developed sophisticated formulation and targeting technology platforms to address options across dermatology and oncology. These deliver treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy. The company is currently focusing on its Skin + CELL luxury skincare range, which includes products that help protect mitochondria to keep cells energetic and healthy, giving skin the ability to protect, repair, and thrive. Additionally, it continues to develop and expand on its dermatology formulation and delivery expertise for many further areas of identified opportunity.
Contact Information
Website
www.incanthera.comCorporate Office
- 98 King Street
- C/O Gateley Legal, Ship Canal House
- Manchester M2 4WU
- England, United Kingdom
Corporate Office
- 98 King Street
- C/O Gateley Legal, Ship Canal House
- Manchester M2 4WU
- England, United Kingdom
Incanthera Stock Performance
As of 18-Nov-2026, Incanthera’s stock price is $0.07. Its current market cap is $9.1M with 138M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.07 | $0.07 | $9.1M | 138M | 351K | -$0.02 |
Incanthera Financials Summary
As of 31-Mar-2026, Incanthera has a trailing 12-month revenue of $16.1K.
|
In Thousands, USD |
TTM 31-Mar-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 2,442 | 2,442 | 14,888 | 14,979 |
| Revenue | 16 | 16 | 0 | 0 |
| EBITDA | (3,046) | (3,046) | (2,473) | (1,851) |
| Net Income | (2,905) | (2,905) | (2,547) | (1,944) |
| Total Assets | 1,361 | 1,361 | 2,199 | 210 |
| Total Debt | 0 | 0 | 0 |
Incanthera Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Incanthera Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Incanthera Comparisons
Industry
Financing
Details
Incanthera Competitors (6)
One of Incanthera’s 6 competitors is Union Therapeutics, a Venture Capital-Backed company based in Hellerup, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Union Therapeutics | Venture Capital-Backed | Hellerup, Denmark | ||||
| Aquapharm Biodiscovery | Formerly VC-backed | Oban, United Kingdom | ||||
| Dermavant Sciences | Formerly PE-Backed | Long Beach, CA | ||||
| Verrica Pharmaceuticals | Formerly VC-backed | West Chester, PA | ||||
| Arcutis Biotherapeutics | Formerly VC-backed | Westlake Village, CA |
Incanthera Patents
Incanthera Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202106934-D0 | Topical formulation | Inactive | 14-May-2021 | ||
| AU-2021318827-A1 | Topical formulation | Pending | 27-Jul-2020 | ||
| CA-3186807-A1 | Topical formulation | Pending | 27-Jul-2020 | ||
| EP-4188325-A1 | Topical formulation | Pending | 27-Jul-2020 | ||
| GB-202011605-D0 | Topical formulation | Inactive | 27-Jul-2020 |
Incanthera Signals
Incanthera Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Incanthera Acquisitions (3)
Incanthera’s most recent deal was a Merger/Acquisition with Enielle. The deal was made on 04-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Enielle | 04-Jun-2026 | Merger/Acquisition | Personal Products | ||
| Incanthera Therapeutics | 28-Jan-2015 | Merger/Acquisition | Drug Discovery | ||
| Onco-NX | 11-Mar-2014 | Merger/Acquisition | Drug Discovery |
Incanthera ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Incanthera Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Onco-NX | Manchester, United Kingdom | 2011 | |
| Incanthera Therapeutics | Manchester, United Kingdom | 2002 |
Incanthera FAQs
-
When was Incanthera founded?
Incanthera was founded in 2010.
-
Where is Incanthera headquartered?
Incanthera is headquartered in Manchester, United Kingdom.
-
What is the size of Incanthera?
Incanthera has 8 total employees.
-
What industry is Incanthera in?
Incanthera’s primary industry is Drug Discovery.
-
Is Incanthera a private or public company?
Incanthera is a Public company.
-
What is Incanthera’s stock symbol?
The ticker symbol for Incanthera is INC.
-
What is the current stock price of Incanthera?
As of 18-Nov-2026 the stock price of Incanthera is $0.07.
-
What is the current market cap of Incanthera?
The current market capitalization of Incanthera is $9.1M.
-
What is Incanthera’s current revenue?
The trailing twelve month revenue for Incanthera is $16.1K.
-
Who are Incanthera’s competitors?
Union Therapeutics, Aquapharm Biodiscovery, Dermavant Sciences, Verrica Pharmaceuticals, and Arcutis Biotherapeutics are some of the 6 competitors of Incanthera.
-
What is Incanthera’s annual earnings per share (EPS)?
Incanthera’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process